P/E ratio for Compugen (CGEN)
P/E ratio as of April 2024 (TTM): -4.70
According to Compugen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.7. At the end of 2022 the company had a P/E ratio of -1.80.
P/E ratio history for Compugen from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.80 | -83.26% |
| 2021 | -10.8 | -67.16% |
| 2020 | -32.7 | 141.63% |
| 2019 | -13.5 | 149.69% |
| 2018 | -5.43 | 56.24% |
| 2017 | -3.47 | -57.79% |
| 2016 | -8.23 | -48.51% |
| 2015 | -16.0 | -55.89% |
| 2014 | -36.2 | 45.68% |
| 2013 | -24.9 | 92.02% |
| 2012 | -12.9 | -8.45% |
| 2011 | -14.1 | -36.76% |
| 2010 | -22.4 | -40.06% |
| 2009 | -37.3 | 3717.53% |
| 2008 | -0.9773 | -74.35% |
| 2007 | -3.81 | -30.87% |
| 2006 | -5.51 | -35.32% |
| 2005 | -8.52 | -17.28% |
| 2004 | -10.3 | -12.3% |
| 2003 | -11.7 | 211.85% |
| 2002 | -3.77 | -52.73% |
| 2001 | -7.97 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Seagen
SGEN | -57.0 | 1,113.67% | 🇺🇸 USA |
 Genetic Technologies GENE | N/A | N/A | 🇦🇺 Australia |
 Teva Pharmaceutical Industries TEVA | -6.39 | 35.96% | 🇮🇱 Israel |
 Eterna Therapeutics ERNA | -0.3812 | -91.89% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.